Skip to main content

OraSure Technologies and the Latino Commission on AIDS Launch HIV Testing Initiative in Recognition of National Latino AIDS Awareness Day, October 15, 2007

OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the launch of a Rapid HIV Testing Initiative in connection with National Latino Awareness Day 2007. This Initiative is being conducted in partnership with the Latino Commission on AIDS with support from the Congressional Hispanic Caucus.

As part of the initiative, OraSure is donating more than 10,000 OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test kits and educational materials to the Latino Commission on AIDS which in turn will distribute the test kits to more than 100 community testing sites and events nationwide.

Since the very dawn of the epidemic, the HIV/AIDS crisis in the U.S. has disproportionately affected the Hispanic/Latino community and to this day the rate of HIV infection in this community continues to rise, said Dennis de Leon, president of the Latino Commission on AIDS. National Latino AIDS Awareness Day is an opportunity to actively change this epidemic by providing education and HIV testing initiatives to help members of the Latino community learn their status earlier to help prevent the further spread of HIV. Rapid HIV tests like OraQuick ADVANCE®, which is a simple, accurate, painless test that uses oral fluid and takes only 20 minutes, are helping us to reach this goal more effectively.

Observed on Monday, October 15, 2007, the fifth-annual National Latino AIDS Awareness Day is a national day of awareness and prevention against HIV/AIDS in the Latino community. With the theme, WAKE UP! TAKE CONTROL! TAKE THE TEST!, National Latino AIDS Awareness Day 2007 is a call to action for Latinos to get tested for HIV.

Created in partnership with the Latino Commission on AIDS, OraSures National Latino AIDS Awareness Day (NLAAD) Rapid HIV Testing Initiative involves the collective support and participation of The Congressional Hispanic Caucus (CHC). To date, several members of the CHC have pledged to publicly unite in the fight against HIV/AIDS by participating in a NLAAD event taking place in their constituency or by issuing an official proclamation in support of the day.

The U.S. Census Bureau estimates the current Latino population at approximately 14 percent, yet nearly 20 percent of all those living with HIV/AIDS in the United States are Latino (CDC, 2005). The Centers for Disease Control and Prevention (CDC) estimates that more than 80,000 Latinos are currently infected with AIDS. Limited access to prevention and care, cultural and language barriers, and immigration status has contributed to this disparity.

We are proud to support National Latino AIDS Awareness Day and to help empower the Latino community by providing access to rapid HIV testing a step that will help to stem the spread of the disease and help HIV positive individuals learn their status earlier, providing the opportunity to protect others and a better opportunity to live a longer, healthier life, said Douglas A. Michels, OraSure's President and Chief Executive Officer. The support of the Latino Commission on AIDS and The Congressional Hispanic Caucus is vital to our work in enabling Latinos nationwide to get tested and learn their HIV status.

National Latino AIDS Awareness Day was created in 2003 by the Latino Commission on AIDS and the Hispanic Federation in partnership with community based organizations, people living with HIV/AIDS, Health Departments and others. More than 1,000 institutions in 350 cities across the continental United States, Puerto Rico and the U.S. Virgin Islands are actively participating in NLAAD 2007 by forging partnerships with like-minded organizations and hosting community events to encourage people to seek HIV testing and counseling.

OraQuick ADVANCE® is the first and only U.S. Food and Drug Administration approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood or plasma specimens.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. For more information on the Company, please go to www.orasure.com.

Contacts:

OraSure Technologies, Inc.
Investor Contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
www.orasure.com
or
Media Contact:
Jennifer Moritz, 917-748-4006
jmoritz@0to5.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.